Name: Sotoxen 120 mg (Sotorasib) Tablets | KRAS G12C Mutated NSCLC Therapy
Brand: Everest Pharmaceuticals
SKU: SOTOXEN-120
Price: 450 USD
Availability: InStock
Rating: 4.6 (8 reviews)

Sotoxen 120 mg (Sotorasib) is a first-in-class, small-molecule, irreversible inhibitor of the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It represents a critical breakthrough in targeted thoracic oncology. Sotoxen is strictly indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor the KRAS G12C mutation, as determined by an FDA-approved test, and who have received at least one prior systemic therapy (such as platinum-based chemotherapy or immune checkpoint inhibitors). By specifically targeting the mutant protein, Sotoxen halts uncontrolled cellular proliferation in a highly specific patient subset that historically lacked direct targeted treatment options.

However, as of January 2025, the FDA officially approved sotorasib in combination with panitumumab (Vectibix) for the treatment of KRAS G12C-mutated metastatic colorectal cancer (mCRC) in patients who have received prior chemotherapy.

Clinical Expert Commentary on Sotoxen 120 mg

“For over forty years, the KRAS mutation was considered the ‘undruggable’ target in oncology. Because the KRAS protein lacks deep binding pockets, developing a small molecule to inhibit its activity eluded clinical science, leaving patients with KRAS-mutated NSCLC reliant entirely on conventional chemotherapy and immunotherapy. The advent of sotorasib changed this paradigm definitively.

By exploiting a temporary pocket created by the specific G12C substitution, we can now covalently lock the mutated protein in an inactive state. However, the financial toxicity of the innovator brand, Lumakras, heavily restricts continuous patient access globally. Integrating high-quality, bioequivalent generics like Sotoxen into our treatment protocols is a critical strategy. It allows oncologists to secure immediate, uninterrupted molecular blockade for these patients, ensuring that survival outcomes are dictated by precise diagnostics and tumor biology, rather than arbitrary economic barriers.” –Dr. Salma Elreedy

Clinical Data, Dosage Guide, & Patient Safety

Precise Indications & Biomarker Requirements

Sotoxen is not a generalized lung cancer treatment. Initiation of therapy requires absolute diagnostic confirmation of a specific molecular target:

Target Indication: Previously treated locally advanced or metastatic NSCLC.
Biomarker Requirement: Confirmed KRAS p.G12C mutation. This must be validated via an approved companion diagnostic test, such as the QIAGEN therascreen KRAS RGQ PCR Kit (for tumor tissue) or the Guardant360 CDx (for circulating tumor DNA / liquid biopsy). It is entirely ineffective against other KRAS variants (e.g., G12D, G12V).

Mechanism of Action & Pharmacokinetics (ADME)

Sotorasib directly inhibits the KRAS G12C mutant protein. It forms an irreversible, covalent bond with the unique cysteine residue at position 12, locking the protein in its inactive GDP-bound state and preventing downstream signaling in the MAPK cascade.

Absorption: Peak plasma concentration (Tmax) is reached at approximately 1 hour. It can be taken with or without food. However, its absorption is highly dependent on gastric pH (see interactions).
Distribution: Highly bound to human plasma proteins (89%).
Metabolism: Primarily hepatic, predominantly mediated by the CYP3A4 enzyme system.
Excretion: Fecal excretion accounts for 74% of the administered dose, with minimal renal clearance (6%). The mean terminal half-life is 5 hours.

Dosage & Adverse Event (AE) Management Protocols

Baseline Dosing: The standard recommended dose is 960 mg taken orally once daily. Because Sotoxen is formulated as 120 mg tablets, this requires the patient to take eight (8) tablets at the same time each day.

Toxicity / Adverse Event	Grade Severity	Clinical Protocol & Dose Modification
Hepatotoxicity (Elevated ALT/AST)	Grade 3 (ALT/AST > 5x ULN)	Withhold Sotoxen until recovery to ≤ Grade 1. Resume at a reduced dose (480 mg daily). If hepatotoxicity recurs, reduce further to 240 mg daily. Permanently discontinue if accompanied by total bilirubin > 2x ULN.
Interstitial Lung Disease (ILD) / Pneumonitis	Any Grade	Withhold Sotoxen immediately for suspected ILD. Permanently discontinue if ILD or pneumonitis is confirmed. Do not attempt dose reduction or re-challenge.
Gastrointestinal Distress (Diarrhea/Nausea)	Grade 3 or 4	Initiate aggressive anti-diarrheal therapy (loperamide). Withhold Sotoxen until recovery to ≤ Grade 1, then resume at the same or a reduced dose depending on clinical judgment.

Table-01: Adverse Event Management

Drug-Drug Interaction Matrix

Clinical Warning: Sotorasib has profound interactions with common over-the-counter gastric medications.

Co-administered Drug Class	Examples	Clinical Interaction	Management Protocol
Gastric Acid-Reducing Agents	Omeprazole, Pantoprazole, Famotidine	Proton Pump Inhibitors (PPIs) and H2-receptor antagonists drastically reduce gastric acidity, leading to a severe decrease in sotorasib absorption and treatment failure.	Avoid co-administration with PPIs and H2 blockers. If an antacid is required, administer Sotoxen 4 hours before or 10 hours after a locally acting antacid (e.g., calcium carbonate).
Strong CYP3A4 Inducers	Rifampin, Phenytoin, St. John’s Wort	Decreases sotorasib plasma concentrations (AUC), risking loss of antineoplastic efficacy.	Avoid concurrent use. Do not attempt to offset by increasing the Sotoxen dose.
CYP3A4 Substrates (Narrow Therapeutic Index)	Fentanyl, Alfentanil, Cyclosporine	Sotorasib is a moderate CYP3A4 inducer. It can decrease the concentrations of these substrates, reducing their effectiveness.	Avoid co-administration. If unavoidable, monitor substrate efficacy closely and adjust the substrate dosage as required.

Table-02: Sotoxen 120 mg Drug Interaction

Clinical Efficacy & Real-World Data

The clinical efficacy of sotorasib in KRAS G12C+ NSCLC is established by the landmark CodeBreaK 100 and CodeBreaK 200 trials:

Efficacy (CodeBreaK 100): In previously treated patients, sotorasib demonstrated an Objective Response Rate (ORR) of 36%, with a median Duration of Response (DoR) of 10 months.
Survival Metrics: Median Progression-Free Survival (PFS) was 6.8 months, and median Overall Survival (OS) reached 12.5 months.
Real-World Evidence (RWE): Post-marketing data indicates that patients who maintain strict compliance with the gastric-pH interaction guidelines (avoiding PPIs) achieve more consistent plasma trough levels, which directly correlates with sustained disease control.

“Note: Sotorasib currently holds accelerated approval for NSCLC based on the objective response rates from CodeBreaK 100. Continued approval may be contingent upon verification of clinical benefit in ongoing confirmatory trials.”

Precautions & Special Populations

Pregnancy: Based on animal data and its mechanism of action, sotorasib can cause fetal harm. Females of reproductive potential must use highly effective contraception during treatment and for at least 1 week following the final dose.
Lactation: It is unknown if sotorasib is excreted in human milk. Breastfeeding is strictly contraindicated during treatment and for 1 week after the final dose.
Pediatric Use: Safety and efficacy in patients younger than 18 years have not been established.
Hepatic/Renal Impairment: No dose adjustment is recommended for mild hepatic or renal impairment. Use with extreme caution in patients with moderate to severe hepatic impairment due to the drug’s inherent hepatotoxic risks.
Storage Logistics: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C. Standard room-temperature logistics apply; cold-chain transport is not required.

Manufacturer Quality Assurance, Global Access, & Brand Comparison

Everest Pharmaceuticals Manufacturing Insights

Sotoxen is manufactured by Everest Pharmaceutical, a specialized oncology producer operating under strict World Health Organization Good Manufacturing Practices (WHO-GMP) and ISO certifications. To ensure precise clinical parity with the innovator brand, Everest mandates rigorous bioequivalence testing. This guarantees that the active pharmaceutical ingredient matches the exact dissolution kinetics and systemic absorption parameters of Lumakras, preserving the narrow therapeutic index required for safe oncological dosing.

Global Access & Personal Importation (NPP)

For patients in regions where Sotoxen is not commercially available, targeted access is achieved through the Named Patient Program (NPP) or designated Personal Importation laws.

Medical Verification: Submit a valid, physically signed prescription from a licensed, treating medical oncologist.
Clinical Justification: Provide a formal Letter of Medical Necessity detailing the confirmed KRAS G12C biomarker status and the clinical requirement for sotorasib over locally available chemotherapy options.
Customs & Ministry of Health (MOH) Clearance: Certified global medical exporters manage all local regulatory documentation, ensuring legal, transparent, and secure transit of the medication directly to the patient or treating hospital.

Brand Comparison

Metric	Lumakras (Innovator)	Sotoxen (Generic)
Active Pharmaceutical Ingredient	Sotorasib	Sotorasib
Dosage Form & Strength	120 mg Oral Tablet	120 mg Oral Tablet
Therapeutic Indications	KRAS G12C-mutated NSCLC	KRAS G12C-mutated NSCLC
Target Mechanism	Irreversible KRAS Kinase Inhibition	Irreversible KRAS Kinase Inhibition
Bioequivalence Level	Originator Standard	Therapeutically Equivalent

Table-03: Brand Comparison

Frequently Asked Questions (FAQs)

How do I take Sotoxen 120 mg correctly?

The standard FDA-approved dose of Sotoxen is 960 mg per day. Because the tablets are 120 mg each, you must take eight (8) tablets all together, once a day, at the same time each day. They can be taken with or without food, but must be swallowed whole.

Can I take my stomach acid medication while on Sotoxen?

No. You must strictly avoid Proton Pump Inhibitors (PPIs like omeprazole) and H2 blockers (like famotidine). These drugs alter the acid in your stomach and prevent Sotoxen from absorbing into your bloodstream, making your cancer treatment ineffective. If you suffer from heartburn, you may use a basic antacid (like Tums/calcium carbonate), but it must be taken 4 hours before or 10 hours after your Sotoxen dose.

Is biomarker testing absolutely mandatory before starting Sotoxen?

Yes. Sotoxen only works on lung tumors that have the specific KRAS G12C mutation. If a patient’s tumor lacks this exact marker (for example, if they have a KRAS G12D mutation), the drug will be entirely ineffective. Your oncologist will order a molecular biopsy test to confirm this before prescribing.

What should I do if I develop a sudden cough or shortness of breath?

You must contact your oncologist immediately. Sotoxen carries a risk of a severe lung condition called Interstitial Lung Disease (ILD) or pneumonitis. Sudden, unexplained respiratory symptoms require immediate medical evaluation, and your treatment may need to be permanently stopped.

How are my liver function levels monitored during treatment?

Hepatotoxicity is a known risk with sotorasib. Your medical team will conduct blood tests to monitor your liver enzymes (ALT, AST, and bilirubin) before starting treatment, every 3 weeks for the first 3 months of treatment, and then once a month as clinically indicated.

What is the price of Sotoxen 120 mg globally?

Sotoxen is formulated as a high-quality generic alternative to Lumakras, positioning it at a highly accessible price point to alleviate the financial toxicity associated with KRAS-targeted care. Exact pricing depends on the patient’s geographic location, customs regulations, and the specific logistics of the Named Patient Program (NPP). Patients must coordinate with their verified global exporter for an exact, case-specific quotation.